Patients with benign essential blepharospasm do not have an increased risk of primary open-angle glaucoma, closed-angle glaucoma or other glaucoma, according to a study. Researchers evaluated Medicare ...

A fascinating new study published in the latest edition of Movements Disorders (Vol.00 No.00, 2016) presents two patient case studies that demonstrate how speaking French as a second language can ...

October 31, 2011 (Orlando, Florida) — A new study shows that shorter injection intervals with incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals), given on an as-needed basis, are safe and effective.

Dear Doctors: I’ve recently been diagnosed with benign essential blepharospasm. Would you please explain what this is? How serious is it? Does it spread? I know it’s not deadly, but I’ve read that it ...

A new study led by investigators from Mass General Brigham demonstrated the use of deep brain stimulation (DBS) to map a 'human dysfunctome' -; a collection of dysfunctional brain circuits associated ...

August 3, 2010 — The US Food and Drug Administration (FDA) has approved incobotulinumtoxinA intramuscular injection (Xeomin; Merz Pharmaceuticals) for the treatment of botulinum toxin–naive and ...

Q I’ve recently been diagnosed with benign essential blepharospasm. Would you please explain what this is? How serious is it? Does it spread? I know it’s not deadly, but I’ve read that it can be ...